TABLE 3

Differences in treatment effects between the bosentan monotherapy and bosentan/metformin combination therapy groups

VariablesChange from baseline mean±sdTreatment effect
mean change (95% CI)
p-value#
BosentanBosentan/metformin
6MWD m48±11995±13652 (10–95)0.017
NT-proBNP ng·L−1−176±325−183±415−141 (−236– −47)0.094
Mean PAP mmHg−12±15−20±19−3 (−7–1)0.145
PVR index WU·m−2−1.2±1.3−1.8±1.2−0.8 (−1.2– −0.4)<0.001
PVR/SVR ratio−0.07±0.19−0.11±0.19−0.10 (−0.63–0.43)0.148
Cardiac index L·min−1·m−20.3±0.50.3±0.40.11 (−0.61–0.28)0.27

6MWD: 6-min walking distance; NT-proBNP: N-terminal pro-brain natriuretic peptide; PAP: pulmonary arterial pressure; PVR: pulmonary vascular resistance; WU: Wood unit; SVR: systemic vascular resistance.#: ANCOVA adjusted for a baseline covariate.